BioAge Labs, Inc. Being Investigated on Behalf of BioAge Labs, Inc. Investors. Contact Levi & Korsinsky For Details
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, ...
BioAge Labs, Inc. (BIOA) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, ...
GEN1d
Insilico Details AI-Designed IBD Candidate’s Path to Nomination
ISM5411 is designed to directly regulate the intestinal immune microenvironment so that the drug simultaneously reduces the gut inflammation seen in IBD while also promoting the repair of the ...
TMCnet2d
BIOA Investors Have Opportunity to Join BioAge Labs, Inc. Securities Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ: BIOA) for ...
Richmond-based BioAge sees stock fall over 70% after halting obesity drug clinical trial
After a lucrative IPO in September, Richmond-based BioAge is seeing its biotech fortunes shift with its stock falling over 70 ...
Fintel on MSN3d
Citigroup Downgrades BioAge Labs (BIOA)
Fintel reports that on December 9, 2024, Citigroup downgraded their outlook for BioAge Labs (NasdaqGS:BIOA) from Buy to ...
kffhealthnews3d
Allina Health’s Response To Workplace Violence Is Not Enough, Nurses Say
CBS News reports that workplace violence at Allina Health's Abbott Northwestern Hospital has led to more than $83,000 in fines over the past year. Other news from the health industry is on the demand ...
Hosted on MSN3d
BioAge Stock Nosedives On Obesity Drug Study Halt: Downgrades Crush Retail Sentiment
BioAge Labs’ stock lost more than two-thirds of its market cap in pre-market trading Monday, poised to hit an all-time low ...
BioSpace3d
BioAge Crashes After Axing Phase II Obesity Study
The discontinuation of STRIDES is a rare stumble for the next-generation obesity field and comes just weeks after Amgen ...
Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns
BioAge Labs halts STRIDES Phase 2 trial of azelaprag after liver enzyme elevations, plans further analysis with updates ...
BioAge Shares Slide Premarket After Obesity Study Halted for Safety
Shares of BioAge Labs plunged nearly 70% in premarket trading Monday after the clinical-stage biopharmaceutical company said it was ending a mid-stage study of its lead program, a proposed obesity ...